Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancers
Conclusion: In this study, we established the role of negative ERCC1 expression in predicting the response to chemotherapy in neoadjuvant TNBC. Therefore, ERCC1 can be used as a predictive marker to stratify patients who will benefit from neoadjuvant therapy. Moreover, we also noted an association b...
Saved in:
| Main Authors: | Atif Ali Hashmi, Yumna Ajaz, Muhsana Sajjad, Fazail Zia, Muhammad Irfan, Syed Muhammad Abu Bakar, Erum Yousuf Khan, Naveen Faridi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | The Breast Journal |
| Online Access: | http://dx.doi.org/10.1155/tbj/8410670 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.
by: Richard A Hubner, et al.
Published: (2011-01-01) -
Kidney Complement Immunohistochemistry in Thrombotic Microangiopathy Subtypes
by: Hannah Beckwith, et al.
Published: (2025-06-01) -
Association of ERCC1 C8092A and ERCC2 Lys751Gln polymorphisms with the risk of glioma: a meta-analysis.
by: Yu Xin, et al.
Published: (2014-01-01) -
ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs
by: T. A. Bogush, et al.
Published: (2020-05-01) -
ERCC1/NGFR affects prognosis in basal-like breast cancer
by: Yuxi Lei, et al.
Published: (2025-07-01)